title: Pharmacokinetics of cladribine in plasma and its 5'-monophosphate and 5'-triphosphate in leukemic cells of patients with chronic lymphocytic leukemia.
abstract: The pharmacokinetic parameters of cladribine (CdA) in patient plasma and its intracellular nucleotides CdA 5'-monophosphate (CdAMP) and CdA 5'-triphosphate (CdATP) were delineated in circulating leukemia cells in 17 patients with chronic lymphocytic leukemia, after the last dose intake and up to 72 h thereafter. Patients were treated with 10 mg/m2 CdA p.o. on 3 consecutive days. A novel and specific ion-pair liquid chromatographic method, which separates the intracellular CdA nucleotides, was used. The area under the concentration versus time curve (AUC) of CdAMP in leukemia cells was generally higher (median, 47 micromol/liter x h) than the AUC of CdATP (median, 22 micromol/liter x h); however, in some patients (3 of 17), the reverse relationship was seen. The median ratio between the AUC values for CdATP and CdAMP was 0.60 (95% confidence interval, 0.4-1.0). The median half-life (t(1/2)) of CdAMP was 15 h, and that of CdATP was 10 h. The median terminal t(1/2) of CdA in plasma was 21 h. A significant correlation was found between the maximum plasma CdA and cellular CdAMP concentrations (r = 0.56, P = 0.02). There was no correlation between the AUC values of cellular CdAMP and CdATP (r = 0.224, P = 0.55). No correlation was found between deoxycytidine kinase activity and intracellular pharmacokinetic parameters of CdAMP or CdATP. The response to treatment was not significantly related to intracellular concentration of CdAMP or active metabolite CdATP. There is great heterogeneity among patients in terms of AUC and t(1/2) of CdAMP and CdATP. Furthermore, the results emphasize the differences between the pharmacokinetics of plasma CdA and those of the metabolites in circulating leukemic cells.
authors.affiliation: Department of Clinical Pharmacology, Karolinska Hospital, Stockholm, Sweden. freidoun.albertioni@fyfa.ki.se
authors.forename: F
authors.initials: F
authors.lastname: Albertioni
authors.forename: S
authors.initials: S
authors.lastname: Lindemalm
authors.forename: V
authors.initials: V
authors.lastname: Reichelova
authors.forename: B
authors.initials: B
authors.lastname: Pettersson
authors.forename: S
authors.initials: S
authors.lastname: Eriksson
authors.forename: G
authors.initials: G
authors.lastname: Juliusson
authors.forename: J
authors.initials: J
authors.lastname: Liliemark
mesh_terms: D000249:Adenosine Monophosphate / Q000031:analogs & derivatives* / Q000097:blood; D000255:Adenosine Triphosphate / Q000031:analogs & derivatives* / Q000097:blood; D000284:Administration, Oral; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000097:blood / Q000493:pharmacokinetics* / Q000627:therapeutic use; D017338:Cladribine / Q000031:analogs & derivatives* / Q000097:blood / Q000493:pharmacokinetics* / Q000627:therapeutic use; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000097:blood* / Q000188:drug therapy*; D008297:Male; D008657:Metabolic Clearance Rate; D008875:Middle Aged; D012044:Regression Analysis
chemical_list: D000970:Antineoplastic Agents; C097601:cladribine triphosphate; D000249:Adenosine Monophosphate; D017338:Cladribine; C112125:cladribine monophosphate; D000255:Adenosine Triphosphate